|
12 March 2007
PI-88 Data to be Presented at Key International Conferences
Brisbane, Australia. 12 March 2007. Progen Industries Limited
(ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II
liver cancer data has been accepted for late breaking news presentation
by the European Association for the Study of the Liver (EASL). Progen
will also be presenting the results of this liver cancer trial at the
American Association for Cancer Research (AACR) Annual Meeting 2007.
In expectation of having
final data fully analysed and ready for disclosure, Progen is planning
for Professor PJ Chen, Principal Investigator of this trial, to present
the 48 week data for all 172 patients that were recruited to this multi-site
Phase II clinical trial. This presentation will take place on Saturday
14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in
Barcelona, Spain from April 11-15, 2007. .
Dr. Anand Gautam, Progen’s VP of Discovery Research, will be presenting
results at the AACR Annual Meeting 2007, which will be held in Los Angeles,
U.S, from April 14-18, 2007.
Further
information:
About Progen:
Progen Industries Limited is an Australian based globally focused biotechnology
company committed to the discovery, development and commercialisation
of small molecule pharmaceuticals for the treatment of cancer and other
serious diseases.
Progen's three key areas of
focus are:
- Clinical Development - via a focused clinical
trial programme involving its two compounds PI-88 and PI-166.
- Drug Discovery - projects focusing on the development
of potent, selective inhibitors of carbohydrate-protein interactions,
which are implicated in many disease processes.
- Manufacturing Services – PI-88 manufacturing
development and supply for the clinical program and contract manufacturing
services.
Keywords -
Progen, liver cancer, PI-88
Web links to selected
recent news and other information about Progen:
|
|